EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Drug Insight: mechanisms and sites of action of ursodeoxycholic acid in cholestasis

Ulrich Beuers

Nature Clinical Practice Gastroenterology & Hepatology · 2006-06 · 3 (6) · 318-328

DOI: 10.1038/ncpgasthep0521 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Nature Clinical Practice Gastroenterology & Hepatology, 2006-06. Verfasst von Ulrich Beuers. Beteiligte Einrichtung: Department of Medicine II, Klinikum Grosshadern, University of Munich, Germany. beuers@med.uni-muenchen.de. Die Arbeit wurde bisher 353-mal zitiert (Crossref) und nennt 85 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Ursodeoxycholic acid (UDCA) exerts anticholestatic effects in various cholestatic disorders. Several potential mechanisms and sites of action of UDCA have been unraveled in clinical and experimental studies, which could explain its beneficial effects. The relative contribution of these mechanisms to the anticholestatic action of UDCA depends on the type and stage of the cholestatic injury. In early-stage primary biliary cirrhosis and primary sclerosing cholangitis, protection of injured cholangiocytes against the toxic effects of bile acids might prevail. Stimulation of impaired hepatocellular secretion by mainly post-transcriptional mechanisms, including stimulation of synthesis, targeting and apical membrane insertion of key transporters, seems to be relevant in more advanced cholestasis. In intrahepatic cholestasis of pregnancy, stimulation of impaired hepatocellular secretion could be crucial for rapid relief of pruritus and improvement of serum liver tests, as it is in some forms of drug-induced cholestasis. In cystic fibrosis, stimulation of cholangiocellular calcium-dependent secretion of chloride and bicarbonate ions could have a major impact. Inhibition of bile-acid-induced hepatocyte apoptosis can have a role in all states of cholestasis that are characterized by hepatocellular bile-acid retention. Different mechanisms of action could, therefore, contribute to the beneficial effect of UDCA under various cholestatic conditions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AnimalsBileCholagogues and CholereticsCholestasisHumansTreatment OutcomeUrsodeoxycholic Acid

Substanzen

Cholagogues and CholereticsUrsodeoxycholic Acid

Autor:innen und Institutionen

  • Department of Medicine II, Klinikum Grosshadern, University of Munich, Germany. beuers@med.uni-muenchen.de

Zitieren

APA

Beuers, U. (2006). Drug Insight: mechanisms and sites of action of ursodeoxycholic acid in cholestasis. Nature Clinical Practice Gastroenterology & Hepatology, 3(6), 318-328. https://doi.org/10.1038/ncpgasthep0521

Vancouver

Beuers U. Drug Insight: mechanisms and sites of action of ursodeoxycholic acid in cholestasis. Nature Clinical Practice Gastroenterology & Hepatology. 2006;3(6):318-328. doi:10.1038/ncpgasthep0521

BibTeX
@article{Beuers2006,
  author = {Beuers, Ulrich},
  title = {Drug Insight: mechanisms and sites of action of ursodeoxycholic acid in cholestasis},
  journal = {Nature Clinical Practice Gastroenterology & Hepatology},
  year = {2006},
  volume = {3},
  number = {6},
  pages = {318--328},
  doi = {10.1038/ncpgasthep0521}
}
Kostenlos starten →